BIOIO
BIOIO Tech is a biotechnology company focused on developing gerotherapies that target the core molecular mechanisms of aging to extend health-span and longevity. Utilizing their proprietary MOAT (Mechanism of Action Technologies) platform, which combines experimental and computational approaches, BIOIO identifies and advances small molecules as bona fide gerotherapies. Their lead clinical application targets metabolic diseases such as diabetes by modulating key metabolic pathways, including fatty acid oxidation and sphingolipid biosynthesis, with first-in-class compounds like BIOIO-1001. The company leverages over two decades of drug mechanism research, big data, and AI-driven virtual screening to accelerate drug development and ensure drug efficacy. BIOIO's approach enables a 'pipeline in a pill' strategy where each asset can be used across multiple clinical indications, positioning the company as a pioneer in aging-related therapeutics with a strong scientific foundation and validated technology platform.
BIOIO
BIOIO Tech is a biotechnology company focused on developing gerotherapies that target the core molecular mechanisms of aging to extend health-span and longevity. Utilizing their proprietary MOAT (Mechanism of Action Technologies) platform, which combines experimental and computational approaches, BIOIO identifies and advances small molecules as bona fide gerotherapies. Their lead clinical application targets metabolic diseases such as diabetes by modulating key metabolic pathways, including fatty acid oxidation and sphingolipid biosynthesis, with first-in-class compounds like BIOIO-1001. The company leverages over two decades of drug mechanism research, big data, and AI-driven virtual screening to accelerate drug development and ensure drug efficacy. BIOIO's approach enables a 'pipeline in a pill' strategy where each asset can be used across multiple clinical indications, positioning the company as a pioneer in aging-related therapeutics with a strong scientific foundation and validated technology platform.